Biovest – from Chapter 11 to the edge of market filing in EU and Canada
This article was originally published in Scrip
After 18 years of development, Biovest International plans to file applications for marketing approval for its personalized therapeutic cancer vaccine BiovaxID by the end of 2012 in Canada, the EU and the US.
You may also be interested in...
Biogen has warned that uptake for its newly approved Alzheimer’s therapy will be slow in the beginning and doctors confirm it will take time to figure which patients can and should be treated.
Public Company Edition: The pace of US initial public offerings slowed a bit in April and May but could ramp back up in June as biopharma investor sentiment rebounds. Also, drug developers continue to go public via SPAC mergers, most recently Valo Health with a $2.8bn post-deal valuation.
Experts say there should be enough Alzheimer’s patients willing to enroll in Biogen/Eisai’s US FDA-required Phase IV trial and other companies’ late-stage studies even with Aduhelm broadly available.